Beth Rhodes
Psychiatric/Mental Health · Prestonsburg, KYNPI 1881274363
Payments from drug & device makers
Across 224 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$285
- Axsome Therapeutics, Inc.$220
- Vanda Pharmaceuticals Inc.$206
- Alkermes, Inc.$198
- Teva Pharmaceuticals USA, Inc.$191
- plus $833 from 8 others
What the payments were for
- Food & beverage$3,69398%
- Education$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 119 | $1,820 |
| AbbVie | 19 | $285 |
| Axsome Therapeutics, Inc. | 12 | $220 |
| Vanda Pharmaceuticals Inc. | 10 | $206 |
| Alkermes, Inc. | 9 | $198 |
| Teva Pharmaceuticals USA, Inc. | 8 | $191 |
| E.r. Squibb & Sons, L.L.C. | 11 | $158 |
| Corium, LLC | 7 | $138 |
| Lundbeck LLC | 6 | $134 |
| Otsuka America Pharmaceutical, Inc. | 7 | $133 |
| Collegium Pharmaceutical, Inc. | 7 | $106 |
| Neurocrine Biosciences, Inc. | 5 | $94 |
| Ironshore Pharmaceuticals Inc. | 3 | $53 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$118
How this compares
$3,752 in reported general payments places this provider in the 85th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $91,556 |
| CaplytaLumateperone Tosylate | 18 | $33,064 |
| Trazodone Hcl | 42 | $1,502 |
| Buspirone Hcl | 58 | $1,258 |
| Sertraline Hcl | 27 | $204 |
| Fluoxetine Hcl | 34 | $195 |
| Quetiapine Fumarate | 23 | $181 |
| Propranolol Hcl | 14 | $159 |
| Duloxetine Hcl | 11 | $149 |
| Hydroxyzine Hcl | 15 | $110 |
| Bupropion XlBupropion Hcl | 11 | $87 |
| Hydroxyzine Pamoate | 14 | $82 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $53 |
| Prazosin Hcl | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $94 | $91,55612 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,820 | $33,06418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Prestonsburg
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
- Hope SmithHopkinsville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.